AC Immune bags FDA fast track designation
Swiss AC Immune and its partner Janssen Pharmaceuticals Inc have been granted FDA Fast Track Designation for their active anti-pTau vaccine ACI-35.030/JNJ-2056 to treat Alzheimer’s disease.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2153 entries already.
Entries by Thomas Gabrielczyk
New targets for incurable blood cancer
A research consortium led by Charité in Berlin has found a protein pattern in 100 patients with the common blood cancer multiple myeloma and 38 healthy controls that independently identifies a poor prognosis and provides new targets for treating the incurable disease.
SynaptixBio Ltd and Evotec SE expand collaboration
Evotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Von der Leyen: no mention of biotechnology
In view of her confirmation as EU Commission President, biotech associations have reminded Ursula von der Leyen of her promise to strategically promote the sector with an EU Biotech Act 2025.
Scientists prevent transplant rejection
Scientists at Hannover Medical School (MHH) have genetically engineered pig lungs in such a way that immunosuppressants could be reduced during transplants.
SOTIO partners with Biocytogen to expand ADC pipeline
Czech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.
Draupnir Bio ApS raises further equity
Targeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
CordenPharma invests €900m in peptide patform expansion
CordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
Catalym raises US$150m
German cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
Sensorion achieves milestones in Phase II trial
French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.